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ABSTRACT
Introduction: Intravenous administration of
parecoxib could provide significant pain relief
in surgical operations that require additional
forms of analgesia. However, very little is
known about its effects on the anxiety levels
of patients before a surgical procedure. The aim
of this prospective study was to investigate
whether intravenous parecoxib, pre-emptively
administered, has an effect on anxiety levels
experienced post-surgically after total knee
arthroplasty (TKA) and if it influences the
reported pain of the procedure itself.
Methods: A total of 90 patients who underwent
TKA under spinal anesthesia were included in
the study. Prior to TKA, all patients received
continuous femoral nerve block (CFNB) and
were randomized into two groups: Group D
consisted of 45 patients who received the drug
parecoxib intravenously in addition to CFNB,
whereas Group P consisted of 45 patients who
received a placebo drug (N/S 0.9 %)
intravenously instead of parecoxib. All patients
were asked to fill in the questionnaires STAI1
and STAI2 in order to evaluate anxiety levels
pre- and post-surgically, respectively. One of the
main aims was to distinguish personality-trait
anxiety from state anxiety, i.e., anxiety
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experience due to the actual perioperative
events and the actual pain endured.
Results: The group receiving parecoxib had
statistically significant lower anxiety levels
both for personality trait anxiety and state
anxiety, as compared to the placebo group.
Conclusions: Based on our findings, parecoxib
had both analgesic and anxiolytic effects in
patients undergoing TKA with CFNB.
Trial Registration: Current Controlled Trials:
NCT02185924.
Keywords: Analgesia; Anxiety; Knee
arthroplasty; Pain relief; Parecoxib; STAI1;
STAI2
INTRODUCTION
Anxiety sensitivity is defined as the trait
tendency to be fearful of anxiety-related
sensations and is also regarded as an
important factor closely associated with the
experience of pain [1]. More specifically, this
unpleasant feeling is commonly referred by
patients during the preoperative period
making them vulnerable to severe pain
following surgery [2]. Patients with greater
pain-related anxiety tend to over-estimate the
intensity of new onset of pain, thus increasing
the likelihood of reported pain [3–7]. In other
words, anxiety sensitivity is not only related to
greater pain experience, but it also predisposes
patients towards more negative sensations of
painful stimuli and, hence, towards a higher
intensity of reported pain.
Continuous femoral block affords a
commonly performed practice in surgical
procedures of total knee arthroplasty (TKA) as
an effective means of providing postoperative
analgesia, while at the same time it reduces side
effects and accelerates functional recovery [8,
9]. Earlier studies highlighted that patients with
pain-related anxiety may benefit from sedatives
and/or tranquilizers during a painful nerve
block procedure [10–13], whereas others
indicated the potential serious complications
that may be caused from the routine use of
benzodiazepines, opioids, and ketamine or
fentanyl, such as prolonged sedation and
amnesic effect after cessation, and
hemodynamic instability among others [10,
14–16].
The analgesic effects of parecoxib
administered perioperatively have been well
documented [17]. Based on data from clinical
trials, the peak serum concentrations of
parecoxib occur approximately 30 min
following intravenous administration and 1 h
after intramuscular injection [18]. However,
very little is known about the effects of
parecoxib on the anxiety levels of patients,
when regularly being administered during the
perioperative period. The aim of this clinical
study was to investigate the effects of
intravenous parecoxib, pre-emptively
administered, on the anxiety levels
experienced during the perioperative period.
METHODS
Ethics Statement
Informed written consent was given by all the
patients prior to enrolment in the study. The
study was also reviewed and approved by the
Institutional Review Board and the Local Ethics
Committee on human research and human
studies at Aretaieion University Hospital with
reference code S-138/15-06-10, and with the
Helsinki Declaration of 1964, as revised in 2013.
Each patient was assigned a code and all data
were analyzed anonymously.
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Patients
A total of 90 patients were included in the
study, all of whom underwent TKA under spinal
anesthesia. Prior to this, all patients received
continuous femoral nerve block under
neurostimulation guidance. Patients were
randomly allocated into two groups in relation
to the placebo/parecoxib administration, as
follows: Group D (n = 45) had parecoxib
40 mg intravenously every 12 h. The first dose
was administered 20 min prior to surgery
completion and for every 12 h within a 48-h
period. Group P (n = 45) received the placebo
drug (N/S 0.9 %) intravenously, instead of
parecoxib.
The randomization process was performed
on the morning of surgery, where patients were
randomized to one of the two aforementioned
groups using computer-generated tables and
sealed drawing-coded opaque envelopes. All
drug solutions were prepared under aseptic
conditions. All persons involved in the clinical
care (surgeons, anesthesiologists and nurses)
and all the patients remained blinded to the
substance and the treatment group assignment.
Exclusion criteria for both groups included: age
younger than 40 years old or older than 80 years
old; ASA [III, obesity ([140 kg body weight);
allergy to local anesthetics, history dependence
on opioids, contraindications for subarachnoid
anesthesia or femoral block (coagulopathy, local
infection, pre-existing neurological problems,
patient refusal); contraindications to the
administration of parecoxib, severe hepatic or
renal disease (serum creatinine C1.7 mg/dl).
Continuous Femoral Nerve Block Under
Neurostimulation Guidance
Local anesthesia with lidocaine 1 % (0.5 mg/kg)
was used to achieve generous skin and
subcutaneous tissue infiltration before the
needle was inserted just inferior to the
inguinal crease, aiming at approximately 45
cephalad. Simultaneously, sedation with
intravenous midazolam 0.05 mg/kg was
administered. Continuous femoral nerve block
was placed in a sterile fashion with neurostim
guidance. Then a SAB (spinal) was placed in a
standard and sterile fashion. Twenty milliliters
of ropivacaine 0.75 % were injected as a bolus
single shot. Later, in recovery following TKA, a
200-ml pump was connected to facilitate an
infusion of 0.2 % at 10 ml/h.
Pain and Anxiety Visual Analog Scales
The evening prior to continuous femoral block
placement, all patients were introduced to using
a 10-cm visual analog scale (VAS) for procedural
pain (0 = no pain at all to 10 = worst pain
imaginable), and got familiar with the
Spielberger State-Trait Anxiety Inventory
(STAI) for adults [19]. More specifically, the
level of pain was assessed and recorded on
preset and agreed times (4, 8, 12, 36, 48 h
postoperatively) whereas approximately
36–48 h following surgery, while under the
influence of parecoxib, all patients were also
requested to fill in a questionnaire, in order to
evaluate anxiety levels pre- and post-surgically;
STAI1 and STAI2, respectively. Of note, all
patients were under the supervision of an
anesthetist blinded to the substance
administered, fully conscious and in
stable clinical condition at the time of the
questionnaire ‘assessment’. The aim of the
questionnaire was to distinguish personality-
or trait-anxiety (T-anxiety) i.e., measure via
self-report the presence and severity of a
generalized propensity to be anxious, from
state anxiety (S-anxiety), i.e., anxiety
experience due to the actual anesthetic/
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analgesic procedure and the actual pain
endured. Therefore, in our study, T-anxiety
can be excluded from the anxiety experienced
because of the perceived threat. The
questionnaire consisted of 20 questions
(State-based) where answers were graded from
1 to 4 (4 = not at all, 3 = somewhat,
2 =moderately so, 1 = very much so) and 20
questions (behavior-based) where answers also
graded from 1 to 4 (4 = almost never,
3 = sometimes, 2 = often, 1 = almost always).
Patients were asked to circle a number as an
answer to each question and the total sum of
numbers in each questionnaire was used to
compare anxiety levels among patients.
Statistical Analysis
The non-parametric Mann–Whitney test was
performed to verify statistically significant
differences between the two groups pre- and
post-operatively, using the IBM SPSS Statistics
program (IBM Corp. Released 2010, IBM SPSS
Statistics for Windows, Version 19.0. Armonk,
NY: IBM Corp).
RESULTS
In the current study, a total of 90 patients were
randomized to placebo (n = 45) and parecoxib
(n = 45). No patient was withdrawn from the
study (Fig. 1). The physical characteristics of the
study groups were comparable; most patients
were female (83.3 %) and all were Caucasians
(100 %). In general, parecoxib provided greater
relief than placebo following TKA; data not
shown. Anxiety levels in both patient groups
are shown in Figs. 2 and 3. More specifically,
anxiety levels of the pre-surgical state (STAI1)
are shown in Fig. 2, whereas anxiety levels of
the post-surgical state (STAI2) are shown in
Fig. 3. Overall, the group receiving parecoxib
had lower anxiety levels both pre- and
post-surgically, as compared to the placebo
group, with statistical significance p = 0.012
and p = 0.002, respectively (Table 1). Precisely,
we demonstrated that 40 mg of intravenous,
even pre-emptively administered parecoxib
improved the anxiety levels experienced
during the perioperative period of TKA.
Consequently, this led to better satisfaction
scores and overall experience for the patients,
regarding pre- and post-procedural pain, as well
as pre- and post-interventional anxiety. Herein,
it should be noted that STAI2 afforded the more
appropriate tool to evaluate the anxiety levels
during the current perioperative period, which
undoubtedly can be very stressful for any
individual. Nevertheless, we considered the
use of STAI1 valuable to extract information
about the patient’s personality, in general. For
example, how patients can cope with stress and
anxiety under normal circumstances.
DISCUSSION
The type of anesthesia affords an imperative risk
factor for postoperative anxiety and, as it has
previously been shown, specifically the neural
blockade could effectively protect patients from
postoperative anxiety through superior
postoperative pain control [2]. In the current
study, we have shown that administration of
parecoxib had statistically significantly
improved anxiety levels for both trait and
state anxiety levels, as compared to the
placebo. Nevertheless, the evaluation of the
state anxiety was the most interesting and
relevant to the current study. This difference,
however, may not have been directly attributed
to parecoxib, at least not post-surgically, as
anxiety reduction might have been due to the
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reduction in procedural pain, i.e., the pain
acting as the mediator, and not due to the
drug itself. At the same time, since we observed
reduced anxiety levels in the pre-surgical state
as well, we proposed that the drug exerted a
positive anxiolytic influence, whether this was
indirectly via reduction of procedural pain, or
directly acting on anxiety levels, or both.
Premedication with midazolam as well as
concomitant use of additional drugs including
opioids and other analgesics given
perioperatively was unlikely to have any direct
impact on anxiolytic effects, since patients were
asked to fill in the questionnaires
approximately 48 h following surgery, which
was at least 12 h following opioid
administration and while patients had
adequate plasma levels of parecoxib following
regular administration. Midazolam was given
even before the block. On the other hand, it
should be noted that patients were still under
parecoxib effect when asked to fill in the
questionnaires.
Potential limitations of the current protocol
should be also taken into consideration. For
instance, one could argue that the anxiety levels
measured were indeed associated with the
personality characteristics and not the
procedure followed, although especially for
this reason STAI was the method of choice.
Nonetheless, the current findings are in
agreement with our previous study that
Assessed for eligibility (n= 90) 
Excluded  (n= 0) 
♦ Not meeting inclusion criteria (n=0) 
♦ Declined to participate (n=0) 
♦ Other reasons (n= 0) 
Analysed  (n=90) 
♦ Excluded from analysis (give reasons) (n=0)
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (give reasons) (n=0) 
Allocated to intervention (n= 90) 
♦ Received allocated intervention (n=90)
♦ Did not receive allocated intervention (give 
reasons) (n= 0)
Lost to follow-up (give reasons) (n= 0) 
Discontinued intervention (give reasons) (n=0) 
Allocated to intervention (n=90) 
♦ Received allocated intervention (n=90)
♦ Did not receive allocated intervention (give 
reasons) (n=0)
Analysed  (n=90 ) 




Randomized (n=90  ) 
Enrollment 
Fig. 1 Consort ﬂow diagram for the study
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investigated whether parecoxib, preemptively
administrated, had an effect on anxiety levels
during epidural catheter placement for surgical
operations. More specifically, we have
previously shown that 40 mg of parecoxib,
administered intravenously 20 min before the
interventional technique, could improve
patients’ anxiety levels, experienced prior to
an epidural catheter placement [17].
Collectively, since intravenous infusion of
parecoxib has been shown to provide
non-steroidal anti-inflammatory
drug-mediated central hyperanalgesia,
attributed to central COX-2 inhibition [20], it
is possible that it also exerts a positive
anxiolytic effect prior to a distressing and
painful procedure such as TKA. In addition,
taking into account the fact that in anxiety the
prefrontal cortex and amygdala, which are
involved in analgesia and hyperanalgesia
demonstrate concurrent areas of activation in
the brain [21], it was only rational to assume
that pre-emptively administered parecoxib was
capable of having an anxiolytic effect prior to
surgery.
Fig. 2 Anxiety levels of the pre-surgical state (STAI1)
between the group receiving parecoxib and the group
receiving placebo. The group receiving parecoxib has
statistically signiﬁcant lower anxiety levels than the placebo
group (p = 0.012)
Fig. 3 Anxiety levels of the post-surgical state (STAI2)
between the group receiving parecoxib and the group
receiving placebo. The group receiving parecoxib has
statistically signiﬁcant lower anxiety levels than the placebo












Mann–Whitney U 683.000 617.500
Wilcoxon W 1718.000 1652.500
Z 2.525 -3.067
Asymp. sig. (two-tailed) 0.012 0.002
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CONCLUSIONS
Our study demonstrated that parecoxib has an
anxiolytic effect in patients undergoing TKA
with continuous femoral block. Nevertheless,
additional studies are necessitated to unravel
the complex relationship and the mechanisms
underlying the association between anxiety and
pain, so as to be able to introduce parecoxib as a
new prophylactic regime or treatment modality
in the management of pain-related anxiety.
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